Vir Biotechnology, Inc. is a pharmaceutical company based in the United States that specializes in immunology. They utilize cutting-edge technologies to develop treatments for serious infectious diseases and other conditions. With a focus on antibodies, T cells, innate immunity, and siRNA, Vir Biotechnology has a diverse pipeline targeting diseases such as hepatitis B, influenza A, HIV, and TB. The company has a medium risk rating score of 29.3 and generates revenue from collaborations, contracts, grants, and licenses. Vir Biotechnology is committed to promoting ESG principles in their operations.